TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04049721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBO
Description: 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: 20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
Study: NCT06392789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Receive sleep education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Receive sleep education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to website content modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to website content modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracker
Study: NCT06143020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
Study: NCT05034510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: modification in stimulation parameters

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: modification in stimulation parameters
Study: NCT06516341

Intervention type: PROCEDURE
Intervention: CD patients
Description: The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery

Intervention type: PROCEDURE
Intervention: UC patients
Description: The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery
Study: NCT04728711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
Study: NCT06380595

Intervention type: PROCEDURE
Intervention: Complex endovascular aortic repair (cEVAR)
Description: Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.

Intervention type: PROCEDURE
Intervention: Complex endovascular aortic repair (cEVAR)
Description: Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.
Study: NCT06392789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive sleep compression SMS conversations
Study: NCT05820828

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volume control
Description: Volume control in venous reservoir during extracorporeal circulation.
Study: NCT05674188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset
Description: Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
Study: NCT06316336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride 10 mg
Description: Alfuzosin Hydrochloride 10 mg (test durg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin Hydrochloride 10 mg
Description: Alfuzosin Hydrochloride 10 mg (test durg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (reference drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (reference drug)
Study: NCT06392789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive sleep compression SMS conversations
Study: NCT06573814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio Gelee Royale Forte
Description: Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
Study: NCT06137482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN13335
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose
Study: NCT06573814

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
Study: NCT06305273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position for face mask ventilation during induction supine
Description: Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in supine position. Participants will be crossed over to the head elevated position after the first measurement is obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position for face mask ventilation during induction head elevated
Description: Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in head elevated position. Participants will be crossed over to the supine position after the first measurement is obtained.
Study: NCT06137482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose
Study: NCT05283083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
Study: NCT05516628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Resection of Primary Hepatocellular Cancer Tumour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Atezolizumab-Bevacizumab Therapy
Description: Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
Study: NCT06137482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered IV or SC, sequential ascending single dose
Study: NCT05732675

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vina-STEAM (Skills to Empower Affirmative Men)
Description: The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vina-STEAM (Skills to Empower Affirmative Men)
Description: The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
Study: NCT06468176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) neuropsychologist
Description: * CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week
Study: NCT04948268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-personalized messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-personalized messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Human coaching to support intervention use and engagement via telephone calls, text or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Human coaching to support intervention use and engagement via telephone calls, text or email

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational links
Description: SMS messages with URLs containing brief psychoeducational information.
Study: NCT04523779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Description: The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
Study: NCT06189872

Intervention type: DEVICE
Group type: OTHER
Intervention: Attune Cementless
Description: * Attune AFFIXIUM Cementless Tibial Baseplate, Fixed Bearing~* Attune POROCOAT Cementless Femoral Component, Cruciate Retaining~* Attune AOX Antioxidant Polyethylene Tibial Insert, Cruciate Retaining~* Attune AOX Patellar Button, Domed or Medialized Dome, Cemented or Cementless (surgeon preference for resurfacing)
Study: NCT05893537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator CT1812
Description: 123 participants will receive a single daily dose of CT1812 (200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 123 participants will receive a single daily dose of placebo
Study: NCT05411198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XEN45 (Glaucoma Gel Stent)
Description: Ab externo implant
Study: NCT04818086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
Study: NCT06435520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy
Description: Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Medication Tapering
Description: A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Medication Tapering
Description: A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
Study: NCT06117540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, 1.1 mg once a day
Study: NCT05380453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg, s.c.
Description: Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Secukinumab, s.c.
Description: Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
Study: NCT06457139

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucose tolerance test (2 hour)
Description: Early testing with the 2 hour glucose tolerance test will occur during their inpatient postpartum hospitalization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of administration of educational materials adapted from the American Diabetes Association that discusses healthy lifestyle behaviors and the increased risks of developing T2DM after a pregnancy complicated by GDM.
Study: NCT04575688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
Study: NCT06393985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, venetoclax and blinatumomab
Description: Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)
Study: NCT05094102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnLume Imaging System
Description: for fluorescence-guided surgery with ICG dye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green is a cyanine dye used in medical diagnostics
Study: NCT04743206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Airway Clearance device
Description: Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Internal Airway Percussion device
Description: Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
Study: NCT05156203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1301 Capsules
Description: T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
Study: NCT06015165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia plan for Anes. Group
Description: For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia plan for Surg. Group
Description: For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-modal analgesia during the surgery
Description: Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal analgesia during the surgery
Description: Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
Study: NCT06034262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX-IP
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
Study: NCT05198986

Intervention type: OTHER
Intervention: Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)
Description: Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
Study: NCT05258396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI without injection of contrast product
Description: MRI without injection of contrast product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI without injection of contrast product
Description: MRI without injection of contrast product